Alonso P, Menchon JM, Pifarre J, et al. Long-term follow-up and predictors of clinical outcome in obsessive-compulsive patients treated with serotonin reuptake inhibitors and behavioral therapy. J Clin Psychiatry. 2001;62(7):535-40.

American Psychiatric Association. Practice guideline for the treatment of patients with obsessive-compulsive disorder. Arlington, VA: American Psychiatric Association, 2007.

Borges G, Angst J, Nock MK, et al. Risk factors for twelve-month suicide attempts in the National Comorbidity Survey Replication (NCS-R). Psychol Med. 2006;36(12):1747-1757.

Catapano F, Perris F, Masella M, et al. Obsessive-compulsive disorder: a 3-year prospective follow-up study of patients treated with serotonin reuptake inhibitors OCD follow-up study. J Psychiatr Res. 2006;40(6):502-10.

Dunner DL. Management of anxiety disorders: the added challenge of comorbidity. Depress Anxiety. 2001;13:57-71.

Eisen JL, Mancebo MA, Pinto A, et al. Impact of obsessive-compulsive disorder on quality of life. Compr Psychiatry. 2006;47(4):270-5.

Foa EB, Kozak MJ. DSM-IV field trial: obsessive-compulsive disorder. Am J Psychiatry. 1995;152(1):90-96.

Foster PS, Eisler RM. An integrative approach to the treatment of obsessive-compulsive disorder. Compr Psychiatry. 2001;42(1):24-31.

Greist J, Jefferson JW, Kobak KA, Katzelnick DJ, Serlin RC. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder: A metaanalysis. Arch Gen Psychiatry. 1995;52:53-60.

Greist JH, Bandelow B, Hollander E, et al. WCA recommendations for the long-term treatment of obsessive-compulsive disorder in adults. CNS Spectr. 2003;8(S1):7-16.

Greist JH, Jefferson JW, Kobak KA, et al. A 1-year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol. 1995;10:57-65.

Hettema JM, Neale MC, Kendler KS. A review and meta-analysis of the genetic epidemiology of anxiety disorders. Am J Psychiatry. 2001;158:1568-1578.

Hollander E, Allen A, Steiner M, et al. Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine. J Clin Psychiatry. 2003;64:1113-112.

Hollander E, Koran LM, Goodman WK, et al. A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder. J Clin Psychiatry. 2003;64:640-647.

Hollander E, Kwon JH, Stein DJ, et al. Obsessive-compulsive and spectrum disorders: overview and quality of life issues. J Clin Psychiatry. 1996;57(Suppl 8):3.

Jenike MA, Baer L, Minichiello WE, et al. Placebo controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder. Am J Psychiatry. 1197;154:1261-4.

Kamijima K, Murasaki M, Asai M, et al. Paroxetine in the treatment of obsessive-compulsive disorder: randomized, double-blind, placebo-controlled study in Japanese patients. Psychiatry Clin Neurosci. 2004;58:427-433.

Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, severity, and comorbidity of twelve-month DSM-IV disorders in the National Comorbidity Survey Replication (NCS-R). Arch Gen Psychiatry. 2005;62(6):617-27.

Kim SJ, Kim CH. The genetic studies of obsessive-compulsive disorder and its future directions. Yonsei Med J. 2006;47(4):443-454.

Kobak KA, Geist JH, Jefferson JW, Katzelnick DJ, Henk HJ. Behavioral versus pharmacological treatments of obsessive compulsive disorder: a meta-analysis. Psychopharmacology. 1998;136:206-216.

Kronig MH, Apter J, Asnis G, et al. Placebo-controlled, multicenter study of sertraline treatment for obsessive-compulsive disorder. J Clin Psychopharmacol. 1999;19(2):172-6.

LaSalle VH, Cromer KR, Nelson KN, et al. Diagnostic interview assessed neuropsychiatric disorder comorbidity in 334 individuals with obsessive compulsive disorder. Depress Anxiety. 2004;19:163-173.

Leon AC, Portera L, Weissman MM. The social costs of anxiety disorders. Br J Psychiatry Suppl. 1995;Apr(27):19-22.

Lipsman N, Neimat JS, Lozano AM. Deep brain stimulation for treatment-refractory obsessive-compulsive disorder: the search for a valid target. Neurosurgery. 2007;61(1):1-11.

Menzies L, Chamberlain SR, Laired AR, et al. Integrating evidence from neuroimaging and neuropsychological studies of obsessive-compulsive disorder: the orbitofrontal-striatal model revisited. Neuroscience Biobehav Rev. 2008;32:525-549.

Montgomery SA, Kasper S, Stein DJ, Bang Hedegarrd K, Lemming OM. Citalopram 20mg, 40mg, and 60mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. Int Clin Psychopharmacol. 2001 Mar;16(2):75-86.

Montgomery SA, McIntyre A, Osterheider M, et al. A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. Eur Neuropsychopharmacol. 1993;3:143-152.

Nelson E, Rice J. Stability of diagnosis of obsessive-compulsive disorder in the Epidemiologic Catchment Area Study. Am J Psychiatry. 1997;154(6):826-831

Norberg MM, Calamari JE, Cohen RJ, Riemann BC. Quality of life in obsessive-compulsive disorder: an evaluation of impairment and a preliminary analysis of the ameliorating effects of treatment. Depress Anxiety. 2008;25(3):248-259.

Overbeek T, Schruers K, Vermetten E, Griez E. Comorbidity of obsessive-compulsive disorder and depression: prevalence, symptom severity, and treatment effect. J Clin Psychiatry. 2002;63(12):1106-12.

Pinto A, Mancebo MC, Eisen JL, Pagano ME, Rasmussen SA. The Brown longitudinal obsessive compulsive study: clinical features and symptoms of the sample at intake. J Clin Psychiatry. 2006;67(5):703-711.

Simpson HB, Foa EB, Liebowitz MR, et al. A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder. Am J Psychiatry. 2008;165(5):621-30.

Stein DJ, Andersen EW, Tonnoir B, Fineberg N. Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study. Curr Med Res Opin. 2007;23(4):701-11.

Stein DJ, Lochner C. Obsessive-compulsive spectrum disorders: a multidimensional approach. Psychiatr Clin of N Am. 2006;29(2):343-351.

Stein DJ. Neurobiology of the obsessive-compulsive spectrum disorders. Biol Psychiatry. 2000;47:296-304.

Swedo SE, Leonard HL, Garvey M, et al. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases. Am J Psychiatry. 1998 Feb;155(2):264-71.

Tollefson GD, Rampey AH, Potvin JH, et al. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry. 1994;51:559-567.

World Health Organization. World Health Report 2001. Mental Health: New Understanding, New Hope. Geneva: WHO, 2001.

Zohar J, Chopra M, Sasson Y, Amiaz R, Amital D. Psychopharmacology of obsessive-compulsive disorder. World J Biol Psychiary. 2000;1(2):92-100.

Zohar J, Judge R, OCD Paroxetine Study Investigators. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. Br J Psychiatry. 1996;169:468-474.